Celldex posts press release on Phase 2 barzolvolimab results in prurigo nodularis

Reuters2026/07/21 20:05

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Celldex released Phase 2 topline data for barzolvolimab in prurigo nodularis; the study missed the primary endpoint at Week 12.
Key secondary endpoints also missed; results did not separate from placebo on itch or lesion measures through Week 24.
Celldex discontinued the Phase 2 prurigo nodularis program; safety was consistent with prior studies despite marked serum tryptase reductions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celldex posts press release on Phase 2 barzolvolimab results in prurigo nodularis

You may also like

Crypto prices